This viewpoint analyzes PsA treatment guidelines, highlighting differences in methodology and stakeholder engagement.
Psoriatic arthritis (PsA) treatment guidelines aim to deliver consistent, evidence-based care across clinical settings. However, the development of multiple regional guidelines often leads to methodological overlap, variability in implementation, and resource redundancy. This Viewpoint compares recent recommendations from ACR, GRAPPA, EULAR, PANLAR exploring their similarities and differences in methodology, structure, and stakeholder composition. We discuss the challenges in maintaining updated recommendations in a rapidly evolving therapeutic landscape and propose a collaborative framework centered on core global recommendations with regional adaptations. Emerging tools, such as living systematic reviews and artificial intelligence, may support more efficient updates, but stakeholder engagement remains essential. Ultimately, a hybrid approach balancing global harmonization with local relevance may enhance the utility and sustainability of PsA guidance.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: